Following the Supreme Court’s Amgen decision last summer,[1] the Federal Circuit has affirmed the invalidity of yet another functionally-defined antibody patent for lack of enablement in Baxalta Inc. v. Genentech, Inc., 81 F.4th 1362 (Fed. Cir. 2023) (mem.).
